Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution.

Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML.

J Infect Dis. 2019 Apr 8. pii: jiz154. doi: 10.1093/infdis/jiz154. [Epub ahead of print]

PMID:
30957170
2.

Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East-Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.

Liu CH, Shih YL, Yang SS, Lin CL, Fang YJ, Cheng PN, Chen CY, Peng CY, Hsieh TY, Chiu YC, Su TH, Liu CJ, Yang HC, Chen PJ, Chen DS, Kao JH.

J Gastroenterol Hepatol. 2019 Apr 1. doi: 10.1111/jgh.14672. [Epub ahead of print]

PMID:
30931537
3.

Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma.

Lam SK, Yan S, Xu S, U KP, Cheng PN, Ho JC.

Oncogenesis. 2019 Feb 26;8(3):18. doi: 10.1038/s41389-019-0128-0.

4.

Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.

Wei L, Kumada H, Perumalswami PV, Tanwandee T, Cheng W, Heo J, Cheng PN, Hwang P, Mu SM, Zhao XM, Asante-Appiah E, Caro L, Hanna GJ, Robertson MN, Haber BA, Talwani R.

J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]

PMID:
30779220
5.

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients.

Cheng PN, Chen JY, Chiu YC, Chiu HC, Tsai LM.

Sci Rep. 2019 Feb 5;9(1):1426. doi: 10.1038/s41598-018-37829-4.

6.

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F.

Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13.

PMID:
30545920
7.

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.

Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS.

J Formos Med Assoc. 2019 Feb;118(2):556-564. doi: 10.1016/j.jfma.2018.11.007. Epub 2018 Dec 5.

8.

Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study.

Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH.

J Formos Med Assoc. 2018 Nov 15. pii: S0929-6646(18)30276-6. doi: 10.1016/j.jfma.2018.10.020. [Epub ahead of print]

9.

Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.

Cheng PN, Chiu HC, Chiu YC, Chen SC, Chen Y.

PLoS One. 2018 Nov 7;13(11):e0206947. doi: 10.1371/journal.pone.0206947. eCollection 2018.

10.

Structural Polymorphs Suggest Competing Pathways for the Formation of Amyloid Fibrils That Diverge from a Common Intermediate Species.

Buchanan LE, Maj M, Dunkelberger EB, Cheng PN, Nowick JS, Zanni MT.

Biochemistry. 2018 Nov 20;57(46):6470-6478. doi: 10.1021/acs.biochem.8b00997. Epub 2018 Nov 6.

11.

Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.

Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1290-1300. doi: 10.1111/apt.15011. Epub 2018 Oct 25.

PMID:
30362139
12.

Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.

Cheng PN, Chiu YC, Chien SC, Chiu HC.

J Formos Med Assoc. 2018 Oct 11. pii: S0929-6646(18)30012-3. doi: 10.1016/j.jfma.2018.09.016. [Epub ahead of print]

13.

Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.

Wei L, Jia JD, Wang FS, Niu JQ, Zhao XM, Mu S, Liang LW, Wang Z, Hwang P, Robertson MN, Ingravallo P, Asante-Appiah E, Wei B, Evans B, Hanna GJ, Talwani R, Duan ZP, Zhdanov K, Cheng PN, Tanwandee T, Nguyen VK, Heo J, Isakov V, George J; C-CORAL Investigators.

J Gastroenterol Hepatol. 2019 Jan;34(1):12-21. doi: 10.1111/jgh.14509. Epub 2018 Dec 9.

PMID:
30311701
14.

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals.

Bazerbachi F, Haffar S, Wang Z, Cabezas J, Arias-Loste MT, Crespo J, Darwish-Murad S, Ikram MA, Olynyk JK, Gan E, Petta S, Berzuini A, Prati D, de Lédinghen V, Wong VW, Del Poggio P, Chávez-Tapia NC, Chen YP, Cheng PN, Yuen MF, Das K, Chowdhury A, Caballeria L, Fabrellas N, Ginès P, Kumar M, Sarin SK, Conti F, Andreone P, Sirli R, Cortez-Pinto H, Carvalhana S, Sugihara T, Kim SU, Parikh P, Chayama K, Corpechot C, Kim KM, Papatheodoridis G, Alsebaey A, Kamath PS, Murad MH, Watt KD.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):54-64.e1. doi: 10.1016/j.cgh.2018.08.069. Epub 2018 Sep 7. Review.

PMID:
30196155
15.

Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer.

Xu S, Lam SK, Cheng PN, Ho JC.

Cancer Sci. 2018 Nov;109(11):3471-3482. doi: 10.1111/cas.13782. Epub 2018 Oct 6.

16.

Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes.

Alexandrou C, Al-Aqbi SS, Higgins JA, Boyle W, Karmokar A, Andreadi C, Luo JL, Moore DA, Viskaduraki M, Blades M, Murray GI, Howells LM, Thomas A, Brown K, Cheng PN, Rufini A.

Sci Rep. 2018 Aug 14;8(1):12096. doi: 10.1038/s41598-018-30591-7.

17.

Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models.

Lam SK, U KP, Li YY, Xu S, Cheng PN, Ho JC.

Oncol Rep. 2018 Oct;40(4):1994-2004. doi: 10.3892/or.2018.6598. Epub 2018 Jul 25.

18.

Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.

George J, Burnevich E, Sheen IS, Heo J, Kinh NV, Tanwandee T, Cheng PN, Kim DY, Tak WY, Kizhlo S, Zhdanov K, Isakov V, Liang L, Lindore P, Ginanni J, Nguyen BY, Wahl J, Barr E, Robertson M, Ingravallo P, Talwani R; C‐CORAL Study Investigators.

Hepatol Commun. 2018 Apr 4;2(5):595-606. doi: 10.1002/hep4.1177. eCollection 2018 May.

19.

Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma.

Tsai HW, Ho CL, Cheng SW, Lin YJ, Chen CC, Cheng PN, Yen CJ, Chang TT, Chiang PM, Chan SH, Ho CH, Chen SH, Wang YW, Chow NH, Lin JC.

World J Gastroenterol. 2018 Mar 14;24(10):1152-1166. doi: 10.3748/wjg.v24.i10.1152.

20.

The characteristics of residents with unawareness of hepatitis C virus infection in community.

Cheng PN, Chiu YC, Chiu HC, Chien SC.

PLoS One. 2018 Feb 22;13(2):e0193251. doi: 10.1371/journal.pone.0193251. eCollection 2018.

21.

Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.

Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC.

World J Gastroenterol. 2018 Feb 14;24(6):725-736. doi: 10.3748/wjg.v24.i6.725.

22.

Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus.

Liu WC, Wu IC, Lee YC, Lin CP, Cheng JH, Lin YJ, Yen CJ, Cheng PN, Li PF, Cheng YT, Cheng PW, Sun KT, Yan SL, Lin JJ, Yang JC, Chang KC, Ho CH, Tseng VS, Chang BC, Wu JC, Chang TT.

J Pathol. 2017 Oct;243(2):176-192. doi: 10.1002/path.4938. Epub 2017 Aug 17. Review.

PMID:
28696069
23.

Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.

Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC.

Gut. 2018 Jul;67(7):1342-1350. doi: 10.1136/gutjnl-2017-313832. Epub 2017 Jun 14.

PMID:
28615303
24.

Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG.

Ho CH, Tsai HW, Lee CY, Huang LJ, Chien RN, Wu IC, Chiu YC, Liu WC, Cheng PN, Chang TT, Chen SH.

Sci Rep. 2017 May 16;7(1):1957. doi: 10.1038/s41598-017-02158-5.

25.

Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.

Lam SK, Li YY, Xu S, Leung LL, U KP, Zheng YF, Cheng PN, Ho JC.

Respir Res. 2017 May 2;18(1):80. doi: 10.1186/s12931-017-0564-3.

26.

Lipoprotein lipase liberates free fatty acids to inhibit HCV infection and prevent hepatic lipid accumulation.

Sun HY, Lin CC, Tsai PJ, Tsai WJ, Lee JC, Tsao CW, Cheng PN, Wu IC, Chiu YC, Chang TT, Young KC.

Cell Microbiol. 2017 Apr;19(4). doi: 10.1111/cmi.12673. Epub 2016 Nov 25.

PMID:
27665576
27.

Prediction of early hepatocellular carcinoma recurrence using germinal center kinase-like kinase.

Ho CH, Chuang HC, Wu IC, Tsai HW, Lin YJ, Sun HY, Young KC, Chiu YC, Cheng PN, Liu WC, Tan TH, Chang TT.

Oncotarget. 2016 Aug 2;7(31):49765-49776. doi: 10.18632/oncotarget.10176.

28.

Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.

Tsai HW, Lin YJ, Wu HC, Chang TT, Wu IC, Cheng PN, Yen CJ, Chan SH, Huang W, Su IJ.

Oncotarget. 2016 May 10;7(19):27724-34. doi: 10.18632/oncotarget.8388.

29.

The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program.

Cheng PN, Chiu YC, Chiu HC, Chien SC.

Medicine (Baltimore). 2016 Mar;95(12):e3193. doi: 10.1097/MD.0000000000003193.

30.

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.

Yang CC, Tsai WL, Su WW, Huang CF, Cheng PN, Lo CC, Tseng KC, Mo LR, Wang CH, Hsu SJ, Lai HC, Su CW, Liu CJ, Peng CY, Yu ML.

PLoS One. 2015 Sep 14;10(9):e0137852. doi: 10.1371/journal.pone.0137852. eCollection 2015.

31.

Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus.

Liu WC, Lin CP, Cheng CP, Ho CH, Lan KL, Cheng JH, Yen CJ, Cheng PN, Wu IC, Li IC, Chang BC, Tseng VS, Chiu YC, Chang TT.

Hepatol Int. 2016 Jan;10(1):147-57. doi: 10.1007/s12072-015-9645-x. Epub 2015 Jul 25.

32.

Qualification and Verification of Serological Biomarker Candidates for Lung Adenocarcinoma by Targeted Mass Spectrometry.

Wu HY, Goan YG, Chang YH, Yang YF, Chang HJ, Cheng PN, Wu CC, Zgoda VG, Chen YJ, Liao PC.

J Proteome Res. 2015 Aug 7;14(8):3039-50. doi: 10.1021/pr501195t. Epub 2015 Jul 13.

PMID:
26120931
33.

Molecular Design for Dual Modulation Effect of Amyloid Protein Aggregation.

Zhu L, Song Y, Cheng PN, Moore JS.

J Am Chem Soc. 2015 Jul 1;137(25):8062-8. doi: 10.1021/jacs.5b01651. Epub 2015 Jun 17.

PMID:
26043045
34.

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.

Yau T, Cheng PN, Chan P, Chen L, Yuen J, Pang R, Fan ST, Wheatley DN, Poon RT.

Invest New Drugs. 2015 Apr;33(2):496-504. doi: 10.1007/s10637-014-0200-8. Epub 2015 Feb 10.

PMID:
25666409
35.

HBsAg expression of liver correlates with histological activities and viral replication in chronic hepatitis B.

Cheng PN, Chiu YC, Tsai HW, Wang RH, Chiu HC, Wu IC, Chang TT.

Ann Hepatol. 2014 Nov-Dec;13(6):771-80.

36.

Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer.

Wang MC, Chang YH, Wu CC, Tyan YC, Chang HC, Goan YG, Lai WW, Cheng PN, Liao PC.

J Thorac Oncol. 2015 Feb;10(2):286-301. doi: 10.1097/JTO.0000000000000396.

37.

Association of serum IgG N-glycome and transforming growth factor-β1 with hepatitis B virus e antigen seroconversion during entecavir therapy.

Ho CH, Chien RN, Cheng PN, Liu CK, Su CS, Wu IC, Liu WC, Chen SH, Chang TT.

Antiviral Res. 2014 Nov;111:121-8. doi: 10.1016/j.antiviral.2014.09.011. Epub 2014 Sep 28.

PMID:
25260899
38.

Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy.

Ho CH, Chien RN, Cheng PN, Liu JH, Liu CK, Su CS, Wu IC, Li IC, Tsai HW, Wu SL, Liu WC, Chen SH, Chang TT.

J Infect Dis. 2015 Jan 1;211(1):115-24. doi: 10.1093/infdis/jiu388. Epub 2014 Jul 10.

PMID:
25015948
39.

Multivalent macromolecules redirect nucleation-dependent fibrillar assembly into discrete nanostructures.

Song Y, Cheng PN, Zhu L, Moore EG, Moore JS.

J Am Chem Soc. 2014 Apr 9;136(14):5233-6. doi: 10.1021/ja501102f. Epub 2014 Mar 31.

PMID:
24661268
40.

Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study.

Tseng KC, Chen CY, Tsai HW, Chang TT, Chuang WL, Hsu PI, Liu WC, Cheng PN.

Antivir Ther. 2014;19(8):755-64. doi: 10.3851/IMP2754. Epub 2014 Feb 28.

PMID:
24583931
41.

Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma.

Cheng SW, Tsai HW, Lin YJ, Cheng PN, Chang YC, Yen CJ, Huang HP, Chuang YP, Chang TT, Lee CT, Chao A, Chou CY, Chan SH, Chow NH, Ho CL.

PLoS One. 2013 Nov 14;8(11):e80053. doi: 10.1371/journal.pone.0080053. eCollection 2013.

42.

Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet.

Buchanan LE, Dunkelberger EB, Tran HQ, Cheng PN, Chiu CC, Cao P, Raleigh DP, de Pablo JJ, Nowick JS, Zanni MT.

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19285-90. doi: 10.1073/pnas.1314481110. Epub 2013 Nov 11.

43.

Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B.

Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT.

J Clin Virol. 2013 Aug;57(4):323-30. doi: 10.1016/j.jcv.2013.04.012. Epub 2013 Jun 2.

PMID:
23731848
44.

The supramolecular chemistry of β-sheets.

Cheng PN, Pham JD, Nowick JS.

J Am Chem Soc. 2013 Apr 17;135(15):5477-92. doi: 10.1021/ja3088407. Epub 2013 Apr 2. Review.

45.

Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates.

Liu C, Zhao M, Jiang L, Cheng PN, Park J, Sawaya MR, Pensalfini A, Gou D, Berk AJ, Glabe CG, Nowick J, Eisenberg D.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):20913-8. doi: 10.1073/pnas.1218792109. Epub 2012 Dec 3.

46.

Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity.

Cheng PN, Liu C, Zhao M, Eisenberg D, Nowick JS.

Nat Chem. 2012 Nov;4(11):927-33. doi: 10.1038/nchem.1433. Epub 2012 Sep 9.

47.

Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma.

Chow AK, Ng L, Sing Li H, Cheng CW, Lam CS, Yau TC, Cheng PN, Fan ST, Poon RT, Pang RW.

Curr Cancer Drug Targets. 2012 Nov 1;12(9):1233-43. Review.

PMID:
22873218
48.

Heterodivalent linked macrocyclic β-sheets with enhanced activity against Aβ aggregation: two sites are better than one.

Cheng PN, Spencer R, Woods RJ, Glabe CG, Nowick JS.

J Am Chem Soc. 2012 Aug 29;134(34):14179-84. doi: 10.1021/ja305416a. Epub 2012 Aug 17.

49.

Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.

Sun HY, Lin CC, Lee JC, Wang SW, Cheng PN, Wu IC, Chang TT, Lai MD, Shieh DB, Young KC.

Gut. 2013 Aug;62(8):1193-203. doi: 10.1136/gutjnl-2011-301798. Epub 2012 Jun 11.

PMID:
22689516
50.

Deprivation of arginine by recombinant human arginase in prostate cancer cells.

Hsueh EC, Knebel SM, Lo WH, Leung YC, Cheng PN, Hsueh CT.

J Hematol Oncol. 2012 Apr 30;5:17. doi: 10.1186/1756-8722-5-17.

Supplemental Content

Loading ...
Support Center